Atrial Fibrillation Treatment Market in 8MM Epidemiology Forecast to 2023

DALLAS, March 5, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "EpiCast Report Atrial Fibrillation - Epidemiology Forecast to 2023" report to its store. The report provides an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets.

Atrial fibrillation (AF) is a disorder of the heart's electrical system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals, resulting in poor blood supply to the lungs and the rest of the body. The symptoms of AF typically include heart palpitations, irregular and fast heartbeat, chest discomfort, shortness of breath, dizziness, and weakness. However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (EKG or ECG) test. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epicast-report-atrial-fibrillation-epidemiology-forecast-to-2023-market-report.html .

Atrial fibrillation is one of the most common cardiovascular diseases among the elderly, worldwide. Although Atrial fibrillation affects people of all ages, the condition is rare in individuals younger than 40 years of age. The risk for Atrial fibrillation increases rapidly with age and is more common in men than women. Globally, the prevalence of AF varies widely, depending on the country and the study, ranging from 0.1-1.6% in Asia (0.1% in India, 1.6% in Japan), 0.95-3.9% in North America (0.95% in the US, 3.9% in Canada), 1.28-2.1% in Europe (1.28% in the UK, 2.1% in Germany), and 4.0% in Australia.

Epidemiologists forecast that the diagnosed prevalent cases of Atrial fibrillation in the 8MM will grow by 21.8% over the next decade, from 10,112,797 diagnosed prevalent cases in 2013 to 12,316,458 diagnosed prevalent cases in 2023. GlobalData's epidemiological forecast for the diagnosed prevalent cases of Atrial fibrillation in the 8MM is supported by epidemiologic data from country-specific studies that are nationally representative of the entire population in these markets. This analysis included the most recently published nationally-representative studies in the 8MM, which provided the diagnosed prevalence of Atrial fibrillation using uniform diagnostic criteria based on EKG tests, which facilitated a meaningful comparison of the forecast for the diagnosed prevalent cases of Atrial fibrillation in the 8MM. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=170326 . (This is a premium report priced at US$3995 for a single user License.)

Scope of this report cover: The Atrial Fibrillation (AF) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF segmented by sex, age (in five-year age groups, beginning at 40 years and ending at =85 years), and clinical subtypes (paroxysmal, persistent, and permanent AF) in these markets; The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists; The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy 

• Develop business strategies by understanding the trends shaping and driving the global AF market.
• Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for AF therapeutics in each of the markets covered.

Explore more reports of Cardiovascular Disease Drugs at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cardiovascular-disease-drugs .

Other Related Reports

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure). Companies discussed in this report include Acorda Therapeutics, Inc., Amgen Inc., Anexon, Inc., AnGes MG, Inc., Angion Biomedica Corp., ARCA biopharma, Inc., Ascelegen Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., Athersys, Inc., Bayer AG, BEAT BioTherapeutics Corp., Bial - Portela & Ca, S.A., Bioheart, Inc., BioLineRx, Ltd., Bristol-Myers Squibb Company, Cardio3 BioSciences SA, Cardioxyl Pharmaceuticals, Inc., Celladon Corporation, Cellmid Limited, FibroGen, Inc., GlaxoSmithKline plc, Glucox Biotech AB, Innopharmax Inc., Jiangsu Hengrui Medicine Co., Ltd., Juventas Therapeutics, Inc., Laboratoires Pierre Fabre SA, Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, Les Laboratoires Servier SAS, Lonestar Heart, Inc., Mast Therapeutics, Inc., Merck & Co., Inc., Mesoblast Limited, Mezzion Pharma Co. Ltd., MI.TO. Technology S.r.L., miRagen Therapeutics, Inc., NeoStem, Inc., Novartis AG, Nyken BV, Ono Pharmaceutical Co., Ltd., Palatin Technologies, Inc., Pfizer Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., QUANTUM GENOMICS Corp., Recardio GmbH, RedHill Biopharma Ltd., RegenoCELL Therapeutics, Inc., Sanofi, Stemedica Cell Technologies, Inc., Target Heart Biotec Srl, Torrent Pharmaceuticals Limited, Trevena, Inc., uniQure N.V., Vicore Pharma AB, Zensun (Shanghai) Sci & Tech Co., Ltd.

Atrial Fibrillation - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report includes ARCA biopharma, Inc., Armetheon, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cardiome Pharma Corp, Daiichi Sankyo Company, Limited, Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., Nyken BV, Otsuka Holdings Co., Ltd., Regado Biosciences, Inc., Serodus ASA, Xention Limited.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 

G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/

Twitter: https://twitter.com/RnRMR

Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research